Molecular therapy for Myocardial dysfunction: Metformin, one of the widely used drugs in the treatment of TIIDM, increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 21/October/2016, 6.15 am

Molecular therapy for Myocardial dysfunction: Metformin, one of the widely used drugs in the treatment of TIIDM, increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 21/October/2016, 6.15 am

Molecular therapy for Myocardial dysfunction: Metformin, one of the widely used drugs in the treatment of TIIDM, increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 21/October/2016, 6.15 am 150 150 Dr Boomi's Genom-2-Discovery Center

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for Myocardial dysfunction: Metformin, one of the widely used drugs in the treatment of TIIDM, increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene



Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


Research Findings: 

This study suggests that a widely known anti-hyperglycemic drug functions as a myocardial protective agent Metformin, by decreasing the expression of its target gene,  it may: (1) increase the expression of marker of autophagy LC3-II, 2) inhibit selective autophagy receptor p62/sequestosome 1 (SQSTM1) expression,  3) inhibit the expression of negative regulator of autophagy, mTOR, 4) promote autophagy, 5) increase CDK inhibitor p27 expression, 6) decrease left ventricular end-diastolic internal diameter and heart size, and (5) inhibit cardiomyocyte dysfunction. Together, this study suggests that pharmacological formulations encompassing “Metformin or its analogs” may be used to improve cardiac function.


Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Myocardial dysfunction: Metformin, one of the widely used drugs in the treatment of TIIDM, increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 21/October/2016, 6.15 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $100#

Undisclosed information: How Metformin promotes autophagy in cardiomyocytes and prevents heart failure.

satisfaction-guaranted-if-not-refunded

Results guaranteed if not refunded